A randomized, double-blind, placebo-controlled, multinational study evaluating the safety and pharmacokinetics of 5 and 10 microg AVE0010 single doses and the efficacy, safety and pharmacokinetics of lixisenatide administered for 5 or 6 weeks, either once or twice daily, following dose escalation from 5 to 30 microg in Japanese and Caucasian type 2 diabetic patients not adequately controlled with sulfonylurea or sulfonylurea and metformin

Trial Profile

A randomized, double-blind, placebo-controlled, multinational study evaluating the safety and pharmacokinetics of 5 and 10 microg AVE0010 single doses and the efficacy, safety and pharmacokinetics of lixisenatide administered for 5 or 6 weeks, either once or twice daily, following dose escalation from 5 to 30 microg in Japanese and Caucasian type 2 diabetic patients not adequately controlled with sulfonylurea or sulfonylurea and metformin

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2014

At a glance

  • Drugs Lixisenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Sanofi-Synthelabo
  • Most Recent Events

    • 08 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top